Saturday 17 October 2026
Export BIIB’s income statement to Excel — free account
Biogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
232.65
2.70
−1.15%
Follow BIIB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
12.75 | 19.93 | 19.61 | 38.04 |
P/S ratio |
2.04 | 2.61 | 2.72 | 3.18 | |
P/FCF ratio |
9.08 | 12.77 | 11.24 | 12.56 | |
P/Operating CF |
16.14 | 50.37 | 41.81 | 71.09 | |
P/B ratio |
1.13 | 1.41 | 1.45 | 1.69 | |
Price to Tangible BV |
8.61 | 9.97 | 8.68 | 0.00 | |
EV/Sales |
2.27 | 2.86 | 2.92 | 3.78 | |
EV/EBITDA |
7.23 | 9.62 | 9.57 | 14.71 | |
EV/Operating CF |
9.32 | 12.82 | 11.19 | 13.17 | |
EV/FCF |
10.11 | 13.99 | 12.07 | 14.93 | |
Quick Ratio |
1.62 | 1.54 | 1.88 | 0.81 | |
Current Ratio |
2.72 | 2.68 | 3.06 | 1.87 | |
Net Debt/EBITDA |
2.72 | 5.84 | 2.83 | 10.18 | |
Debt/Assets |
21.52% | 21.35% | 21.33% | 22.72% | |
Debt/Equity |
0.35 | 0.34 | 0.34 | 0.39 | |
Asset Turnover |
0.35 | 0.34 | 0.35 | 0.33 | |
Operating CF/Net income |
2.73 | (10.47) | 2.02 | 4.60 | |
Capex/Depreciation |
(0.20) | (0.19) | (0.16) | (0.40) | |
Research and Development Expense of Revenue |
17.21% | 22.35% | 21.75% | 19.36% | |
Selling, General and Administrative Expense of Revenue |
23.47% | 29.94% | 24.51% | 25.94% | |
Intangible Assets out of Total Assets |
0.54 | 0.53 | 0.53 | 0.64 | |
Share Based Compensation of Revenue |
2.97% | 2.61% | 3.39% | 2.83% | |
Graham Net Nets |
(0.10) | (0.09) | (0.06) | (0.19) | |
Graham Number |
175.25 | 157.35 | 163.27 | 127.71 | |
Earnings Yield |
7.85% | 5.02% | 5.10% | 2.63% | |
Free Cash Flow Yield |
11.02% | 7.83% | 8.90% | 7.96% | |
Revenue per Share |
17.29 | 15.56 | 16.83 | 18.52 | |
Operating CF per Share |
8.68 | 3.49 | 4.39 | 3.04 | |
Capex per Share |
(0.35) | (0.41) | (0.35) | (1.19) | |
Free Cash Flow per Share |
8.33 | 3.08 | 4.04 | 1.85 | |
Cash per Share |
27.02 | 26.05 | 29.09 | 8.70 | |
Shareholders Equity per Share |
124.20 | 124.62 | 126.71 | 127.61 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
124.20 | 124.62 | 126.71 | 127.61 | |
Free Cash Flow |
1,221.00 | 451.70 | 594.30 | 273.00 | |
Working Capital |
5,646.60 | 5,624.70 | 6,191.50 | 3,388.60 | |
Capital Expenditures |
(51.50) | (60.20) | (51.20) | (175.90) | |
Net Current Asset Value |
(2,063.40) | (2,208.60) | (1,641.00) | (5,932.90) | |
EV/EBIT |
10.37 | 15.17 | 15.42 | 30.63 | |
Capex to Sales |
0.02 | 0.03 | 0.02 | 0.06 | |
Price to Operating Income |
9.31 | 13.85 | 14.36 | 25.78 | |
| Other line items | |||||
Average Receivables |
1,455.15 | 1,373.60 | 1,682.85 | 1,754.90 | |
Average Payables |
417.90 | 428.10 | 375.00 | 406.15 | |
Average Inventory |
2,339.30 | 2,314.30 | 2,111.45 | 2,329.30 | |
Average Assets |
28,760.35 | 28,744.40 | 28,758.10 | 30,208.40 | |
Average Common Equity |
17,283.20 | 17,486.40 | 17,815.20 | 18,241.00 |
Columns are period end dates